Ruifeng Shi

738 citations
46 papers · 493 indexed · h-index 14
Topics
Lung Cancer Treatments and Mutations (11 papers)RNA modifications and cancer (10 papers)Epigenetics and DNA Methylation (9 papers)
Journals
SHILAP Revista de lepidopterologíaPLoS ONEScientific Reports
Partner nations
ChinaUnited StatesSweden

In The Last Decade

Ruifeng Shi

42 papers receiving 489 citations

Peers

Ruifeng Shi
Comparison fields: 5 of 78
  • Molecular Biology 233
  • Pulmonary and Respiratory Medicine 130
  • Cancer Research 105
  • Oncology 100
  • Epidemiology 74
Replace Cheng Qian with:
Cheng Qian China
Zhibo Chen China
Morteza Abouzaripour Iran
Alexandre Hego Belgium
Junfa Chen China
Yicun Wang China
Delia Projahn Netherlands
Anke C. Fender Germany
Bingyan Shu China
Keqiang Zuo China
Ruifeng Shi relative to Cheng Qian China Cheng Qian's profile →
Citations per field
00.5×1.5×1.9×
Cheng Qian · 1×
Citations per year

Countries citing papers authored by Ruifeng Shi

Since Specialization
Citations

This map shows the geographic impact of Ruifeng Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruifeng Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruifeng Shi more than expected).

Fields of papers citing papers by Ruifeng Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruifeng Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruifeng Shi. The network helps show where Ruifeng Shi may publish in the future.

Co-authorship network of co-authors of Ruifeng Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Ruifeng Shi. A scholar is included among the top collaborators of Ruifeng Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruifeng Shi. Ruifeng Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 5
2 0
3 0
4 1
5 1
6 1
7 1
8 11
9 3
10 9
11 15
12 3
13 29
14 34
15 8
16 3
17 12
18 17
19 15
20 9

About Ruifeng Shi

Ruifeng Shi is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 46 papers that have together received 493 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (11 papers), RNA modifications and cancer (10 papers) and Epigenetics and DNA Methylation (9 papers). The work is most often cited by research in Cancer Research (105 citations), Internal Medicine (20 citations) and Pulmonary and Respiratory Medicine (130 citations). Ruifeng Shi has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Jun Chen, Li Y, Zihe Zhang, M. Liu, Hongbing Zhang, Guangsheng Zhu, Hongyu Liu, Hongyu Liu, Zhenhua Pan and Hao Gong. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026